We identified 148 446 patients aged ≥66 years with atrial fibrillation who began warfarin therapy over the study period, and of these patients, 6006 experienced an ischemic stroke. Of Background and Purpose-Recent evidence suggests that there may be an increased risk of ischemic stroke immediately after warfarin initiation. We examined the rate of ischemic stroke among patients with atrial fibrillation newly started on warfarin therapy. Methods-We conducted a population-based cohort study among Ontario residents aged ≥66 years with atrial fibrillation who received warfarin between April 1, 1997, and March 31, 2010. Each patient was followed up for ≤5 years in 30-day intervals. For each interval, we determined the rate of ischemic stroke. Results-After 5 years, the cumulative incidence of ischemic stroke among new users of warfarin (n=148 446) was 4.0% (n=6006). The risk was highest during the first 30 days after initiation (6.0% per person-year; 95% confidence interval, 5.5%-6.4%) compared with the remainder of follow-up (1.6% per person-year; 95% confidence interval, 1.5%-1.6%), and increased with higher baseline CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke) scores. Less frequent monitoring may have contributed. Conclusions-In a large cohort of older patients with atrial fibrillation, we observed the highest rate of ischemic stroke in the first 30 days after warfarin initiation. Although causation cannot be established given the observational nature of this study, our findings highlight the need for future research in this population. 
W
arfarin is effective for the prevention of ischemic stroke and systemic embolism in patients with atrial fibrillation. 1 However, the inconvenience of laboratory monitoring and risk of hemorrhage can complicate therapy. The risk of major hemorrhage is greatest within the first 30 days of therapy, 2 and a recent case-control study in atrial fibrillation patients found a 71% increased risk of ischemic stroke in the first 30 days of warfarin therapy. 3 Remaining unclear is the absolute risk of ischemic stroke throughout the course of warfarin therapy and whether it is influenced by patient characteristics. The objective of this study was to examine whether an acute risk of ischemic stroke exists among patients with atrial fibrillation newly initiated on warfarin.
Methods
We conducted a population-based cohort study of Ontario residents aged ≥66 years who received warfarin between April 1, 1997, and March 31, 2010. The primary outcome was a hospital visit (inpatient or emergency department admission) for ischemic stroke. We assessed various baseline characteristics (Table 1; Table I in the online-only Data Supplement) and followed up each patient from warfarin initiation until the first of ischemic stroke, death, warfarin discontinuation, end of the maximum 5-year follow-up, or the end of the study period (March 31, 2012; online-only Data Supplement). The Research Ethics Board of Sunnybrook Health Sciences Center, Toronto approved this study.
Crude rates were calculated in 30-day intervals as the total number of participants with a hospital visit for ischemic stroke divided by the number of event-free warfarin users at the beginning of each interval and expressed as percentage per person-year (PPY). We stratified all analyses by CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke) score and stroke history, 4 and used the Cochrane-Armitage test for trend and χ 2 tests to identify differences in crude stroke rates. We performed a sensitivity analysis for timing of atrial fibrillation diagnosis.
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the patients who experienced an event, 27.3% (n=1639) died in hospital or within 7 days of discharge. The 30-day cumulative incidence of ischemic stroke among new users of warfarin was 0.5% (n=721), increasing to 2.0% (n=2,917) after 1 year, 2.7% (n=4067) after 2 years, and 4.0% (n=6006) after 5 years. The risk was highest during the first 30 days of warfarin therapy: 6.0% PPY (95% confidence interval, 5.5%-6.4%) versus 1.6% PPY (95% confidence interval, 1.5%-1.6%) during the remainder of the 5-year follow-up (Table 2; Figure) .
Crude 5-year rates of ischemic stroke increased significantly as CHADS 2 scores increased (P<0.0001; Table 2 ; Figure I in the online-only Data Supplement) and among those with a history of stroke (P<0.001; Table 2 ; Figure II in the onlineonly Data Supplement). A sensitivity analysis demonstrated no difference in stroke rates according to timing of warfarin initiation after atrial fibrillation diagnosis (Table 2 ). Relative to patients who did not experience a stroke, those who did were less likely to have received an international normalized ratio test in the preceding 14 days ( 
Discussion
In this population-based study, the rate of ischemic stroke in older patients with atrial fibrillation starting warfarin was significantly elevated during the first month of treatment. This early elevated risk increased with previous stroke history and higher baseline CHADS 2 score.
The overall 5-year risk of stroke observed in our study (1.8% PPY) is comparable with the annual incidence rate of 1.66% (95% confidence interval, 1.41%-1.91%) reported in a meta-analysis of 8 randomized controlled trials and an observational study by Azoulay et al, 3, 5 but higher than the rate of 1.17% PPY reported in another observational study of younger patients with lower CHADS 2 scores. 1 The explanation for our findings is likely multifactorial. The results may reflect the high-risk period after a transient ischemic attack, 6 and the time required to achieve therapeutic anticoagulation. Less frequent international normalized ratio testing may have been a contributor. More research is needed to elucidate whether a transient hypercoagulable state seen immediately after warfarin initiation explains our findings. 7 Our sensitivity CHADS 2 indicates score comprised of congestive heart failure, hypertension, age ≥75 years, diabetes, previous stroke; and IQR, interquartile range. analysis stratifying patients by timing of warfarin initiation after atrial fibrillation diagnosis found similar stroke rates in both groups. This suggests our findings are not simply influenced by elevated rates of stroke after atrial fibrillation diagnosis, as has been previously reported. 8 Moreover, few patients received heparins or antiplatelet agents before initiating warfarin. Studies are needed to determine whether bridging therapy, antiplatelet therapy, or use of direct-acting anticoagulants mitigate this early increased stroke risk.
Table 2. Rates of Stroke by Duration of Warfarin Therapy
Strengths of this study include its large, populationbased sample and long follow-up. Limitations include our inability to assess the quality of anticoagulation. We also could not capture stroke events that did not result in hospitalization or some important risk factors for stroke, such as hypertension.
Conclusions
In this large, population-based cohort study of older patients with atrial fibrillation, we observed the highest rate of ischemic stroke in the first 30 days after warfarin initiation. Although this does not provide evidence of a causal link between warfarin initiation and stroke, the persistence of thromboembolic risk despite anticoagulation highlights the need for future research in this area.
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Data sources
We identified prescription drug data using the Ontario Drug Benefits (ODB) program database, which captures records of all drugs dispensed to Ontario patients aged 65 years and older. To identify hospital and emergency department (ED) visits (including diagnoses and procedures), we used the Canadian Institute for Health Information's Discharge Abstract Database (CIHI-DAD) and the National Ambulatory Care Reporting System (NACRS), respectively. To identify physician visits, we accessed the Ontario Health Insurance Plan (OHIP) database which contains diagnostic information for all inpatient and outpatient physician visits.
We stratified patient outcomes by CHADS 2 score, which denotes stroke risk in patients with atrial fibrillation. [1] The score assigns 1 point each for congestive heart failure, hypertension, age 75 years or greater, and diabetes mellitus, and 2 points for previous ischemic stroke or systemic embolism. To calculate the CHADS 2 score, we used the Ontario Diabetes Database, the Ontario Congestive Heart Failure Database, and the Ontario Hypertension Database, all of which have high sensitivity and specificity. [2] [3] [4] Prior ischemic stroke was identified through the CIHI-DAD and the NACRS. The Registered Persons Database was used to obtain demographic characteristics, including date of birth, sex, and date of death. All databases used in this study are linked using encrypted health-card numbers at the Institute for Clinical Evaluative Sciences (ICES, www.ices.on.ca), and are used routinely in drug safety research. [5, 6] 
Identification of the cohort
We identified a cohort of new warfarin users between April 1 st , 1997 and March 31 st , 2010. Cohort entry was defined as the date of first warfarin prescription fill after the participant's 66 th birthday. We did not include participants during the first year of ODB eligibility (age 65) to avoid incomplete records. We included only patients who had an ED visit, outpatient physician visit or hospitalization for atrial fibrillation in the 100 days prior to cohort entry (International Classification of Diseases, 9 th Revision (Clinical Modification) code 427. 3 
; International Statistical Classification of Diseases and Related Health Problems, 10
th Revision codes I48.0 or I48.1; OHIP diagnosis code 427). We excluded patients who had missing age or sex data, and those who had any prior prescriptions for warfarin, rivaroxaban, apixaban, or dabigatran in the previous 365 days.
Warfarin Exposure
We defined continuous warfarin therapy as consecutive prescription refills within 180 days of the previous prescription. If the prescription was not refilled within 180 days, patients were considered to have discontinued warfarin therapy, and the date of discontinuation was defined as 100 days after the date of the last prescription.
Risk of Ischemic Stroke
The primary outcome was hospitalization or ED visits for ischemic stroke. We followed each patient from warfarin initiation until the first of ischemic stroke, death, warfarin discontinuation, end of the maximum 5-year follow-up, or end of the study period (March 31, 2012). Only the first ischemic stroke event over the follow-up period was included in the analysis.
Patient characteristics
We determined baseline characteristics for all cohort members, and assessed the concomitant use of antiplatelet drugs and other medications that may affect stroke risk from patients' prescription drug claims in the 120 days prior to cohort entry. We also assessed prescriptions for heparins and other anticoagulants, as these may have been used for bridging therapy to decrease the risk of thromboembolic events early in warfarin therapy. We assessed comorbidity using the Charlson comorbidity index [7] , the total number of drugs received in the previous year [8] , and the prevalence of a number of specific comorbid conditions in the past 3 years.
In the absence of laboratory data, we used the frequency of international normalized ratio (INR) testing as a surrogate measure of the intensity of patient monitoring. For patients who received warfarin for at least 365 days, we measured the mean number of INR tests conducted per person during the first year of follow up. In a separate analysis, we also compared the prevalence of INR tests 7 and 14 days prior to ischemic stroke. We created a comparator group by randomly assigning index dates to patients who had not experienced an ischemic stroke during follow-up using the same temporal distribution as the ischemic stroke dates. The prevalence of INR testing for the period prior to the index dates for the two groups was then compared using chi-square tests.
Statistical Analysis
We divided the follow-up period into 30-day intervals. For each interval after cohort entry, we calculated both crude and adjusted rates of ischemic stroke. Crude rates were calculated as the total number of participants with a hospital or ED visit for ischemic stroke divided by the number of event-free warfarin users at the beginning of the interval. These rates were also expressed as percentage per person-year, adjusting for patient dropout due to death and drug discontinuation during follow-up. We stratified all analyses by CHADS 2 score and stroke history, and used the Cochrane-Armitage test for trend and chi-squared tests to identify differences in crude ischemic stroke rates. Studies have suggested that ischemic stroke risk is highest in the 30 days after first diagnosis of atrial fibrillation. [9, 10] Therefore, we performed a sensitivity analysis, stratifying individuals according to whether their first recorded atrial fibrillation diagnosis was more than 30 days prior to warfarin initiation. We identified atrial fibrillation diagnoses as early as August 1996 for OHIP and CIHI-DAD and July 2000 for NACRS. All analyses were conducted using SAS software, Version 9.2 of the SAS System for Unix (SAS Institute Inc., North Carolina). Congenital stenosis of aortic valve 746. 4 Congenital insufficiency of aortic valve 746. 5 Congenital mitral stenosis 746. 6 Congenital mitral insufficiency V42. 2 Heart valve V43. 3 Heart valve Thromboembolism (Pulmonary embolism and deep vein thrombosis) ICD10 Codes I26.0
SUPPLEMENTAL TABLES
Pulmonary embolism with mention of acute cor pulmonale I26. 9 Pulmonary embolism without mention of acute cor pulmonale I80. 1 Phlebitis and thrombophlebitis of femoral vein I80. 2 Phlebitis and thrombophlebitis of other deep vessels of lower extremities I80. 3 Phlebitis and thrombophlebitis of lower extremities, unspecified I80. 8 Phlebitis and thrombophlebitis of other sites I80. 9 Phlebitis and thrombophlebitis of unspecified site I82. 8 Embolism and thrombosis of other specified veins I82. 9 Embolism and thrombosis of unspecified vein ICD9 Codes 415.0
Acute cor pulmonale 415.1 Pulmonary embolism 451. 1 Of deep vessels of lower extremities 451. 2 Of lower extremities, unspecified 451. 8 Of other sites 451. 9 Of unspecified site 453. 8 Of other specified veins 453. 9 Of unspecified site 
